Cargando…
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
Improvement of cancer therapy by introducing new concepts is still urgent even though there have been major advancements lately. Immunotherapy is well on the way to becoming an established tool in the cancer treatment armory. It seems that a combination of (1) activation of immune effector cells and...
Autores principales: | Eisen, Tim, Hedlund, Gunnar, Forsberg, Göran, Hawkins, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918406/ https://www.ncbi.nlm.nih.gov/pubmed/24445502 http://dx.doi.org/10.1007/s11912-013-0370-0 |
Ejemplares similares
-
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017) -
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
por: Schoumacher, Marie, et al.
Publicado: (2017) -
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
por: Joharatnam-Hogan, Nalinie, et al.
Publicado: (2021) -
Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock
por: Almaida-Pagan, Pedro F., et al.
Publicado: (2022) -
WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)